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OBJECTIVES: Prophylactic dalteparin reduces the 
incidence of deep venous thrombosis (DVT) after hip
replacement. The aim of this analysis is to perform a
pharmacoeconomic evaluation of prolonged (35 day)
versus short (7 day) prophylaxis with dalteparin for this
indication. METHODS: A cost-effectiveness analysis was
carried out by building a decision analytic model. Effec-
tiveness data were taken from a meta-analysis of all clin-
ical trials (CT) of dalteparin in prolonged prophylaxis
after hip replacement. After pooling and analyzing all CT
found, the incidence of DVT was 6.1% with a prolonged
prophylaxis and 15.1% when using a short prophylaxis.
Health care resources utilization with dalteparin was
taken from the aforementioned meta-analysis and a local
expert panel. Only direct medical costs were included in
the model (drug acquisition, length of hospital stay, diag-
nostic procedures and treatment of DVT cases). Drug
acquisition cost data were obtained from ofﬁcial sources
while the rest of the data were taken from a national
Health care cost database. The perspective selected for
this analysis was the National Health Service and the 
time horizon chosen was 35 days, being the maximum
time that patients received dalteparin as prophylaxis.
RESULTS: In two hypothetical cohorts of 500 patients,
424 patients reported no DVT cases in the prolonged pro-
phylaxis group resulting in a cost/patient free of DVT of
€370 whilst 469 patients in the short prophylaxis group
reported no DVT thereby giving a cost/patient free of
DVT of €611. CONCLUSION: This pharmacoeconomic
analysis demonstrates that prolonged prophylaxis with
dalteparin is a more efﬁcient alternative than short pro-
phylaxis, as it presents better clinical results with lower
associated costs and a lower cost/effectiveness ratio.
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OBJECTIVES: Widespread use of automated external
deﬁbrillators by policemen and ﬁre ﬁghters in the Nether-
lands may shorten the time to shock in out-of-hospital
cardiac arrest (OHCA). This study assessed the average
health care costs per life saved and the incremental cost-
effectiveness ratios for three different “reduced time to
shock’s cenarios. METHODS: Between January 2000 and
January 2002 all consecutive patients in witnessed OHCA
in Amsterdam, with ventricular ﬁbrillation as initial
rhythm, identiﬁed by the dispatch center, were included.
Each patient’s time to shock was estimated and assigned
to one of 3 categories: <7 minutes (early), 7–12 minutes
(intermediate), and >12 minutes (late). Clinical data and
health care costs were prospectively collected at patient
level for the ﬁrst half-year after collapse. RESULTS: A
total of 308 patients were included. Six-month survival
was 22%. The mean pre-, in-, and post-hospital costs
were €559, €6,870, and €666, respectively. On average,
€28,636 were spent per survivor and €2,384 per non-
survivor. Among patients shocked early (N = 24), 46%
survived, averaging €20,253, whereas 54% died, averag-
ing €2,836. Of the intermediate group (N = 149) 26%
survived, averaging €31,467, and 74% died, averaging
€2,884. Among patients shocked late (N = 135), 13%
survived, averaging €27,781, 87% died, averaging
€1,859. The incremental cost-effectiveness ratios for
reductions of time from late to intermediate, late to early,
and intermediate to early were €37,376, €16,679, and
€3,225 respectively. CONCLUSIONS: Most costs after
OHCA were made in-hospital. Mean costs per survivor
were lowest with the shortest time to shock. Reduced time
to shock scenarios showed incremental health care costs
per life saved, which were well within acceptable societal
limits. It is most efﬁcient to put all effort in optimizing
for shock delivery within seven minutes after the collapse.
Further study should be directed at the program costs of
measures to ensure early shock delivery.
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OBJECTIVES: Coronary heart disease (CHD) is the
single commonest cause of premature death in the UK 
and is a major priority for the NHS. A stochastic 
decision model was developed to establish the cost-
effectiveness of treating new hypercholesterolaemic
patients to European target levels of blood total choles-
terol (TC) and low density lipoprotein-cholesterol (LDL-
C), using either rosuvastatin, atorvastatin, simvastatin,
pravastatin or ﬂuvastatin. METHODS: The model was
used to estimate the proportion of patients reaching target
and the associated costs over a 1-year period from the
perspective of the NHS. The effectiveness of the alterna-
tive statins were modelled using the percentage reductions
in TC and LDL-C principally derived from the Statin
Therapies for Elevated Lipid Levels compared Across
doses to Rosuvastatin (STELLAR) trial (n = 2341).
Second order probability distributions and Monte Carlo
simulations were used to reﬂect parameter uncertainty.
